These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27817208)

  • 1. Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
    Bays H; Pi-Sunyer X; Hemmingsson JU; Claudius B; Jensen CB; Van Gaal L
    Curr Med Res Opin; 2017 Feb; 33(2):225-229. PubMed ID: 27817208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
    Blackman A; Foster GD; Zammit G; Rosenberg R; Aronne L; Wadden T; Claudius B; Jensen CB; Mignot E
    Int J Obes (Lond); 2016 Aug; 40(8):1310-9. PubMed ID: 27005405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
    Ard J; Cannon A; Lewis CE; Lofton H; Vang Skjøth T; Stevenin B; Pi-Sunyer X
    Diabetes Obes Metab; 2016 Apr; 18(4):430-5. PubMed ID: 26744025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
    van Can J; Sloth B; Jensen CB; Flint A; Blaak EE; Saris WH
    Int J Obes (Lond); 2014 Jun; 38(6):784-93. PubMed ID: 23999198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
    Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
    Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
    JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
    Guo W; Tian W; Lin L; Xu X
    Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS.
    O'Neil PM; Garvey WT; Gonzalez-Campoy JM; Mora P; Ortiz RV; Guerrero G; Claudius B; Pi-Sunyer X;
    Endocr Pract; 2016 Nov; 22(11):1277-1287. PubMed ID: 27482610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
    Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
    Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
    von Scholten BJ; Davies MJ; Persson F; Hansen TW; Madsbad S; Endahl L; Jepsen CH; Rossing P
    J Diabetes Complications; 2017 Jul; 31(7):1164-1168. PubMed ID: 28462892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Klein DJ; Battelino T; Chatterjee DJ; Jacobsen LV; Hale PM; Arslanian S;
    Diabetes Technol Ther; 2014 Oct; 16(10):679-87. PubMed ID: 25036533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.
    Niswender K; Pi-Sunyer X; Buse J; Jensen KH; Toft AD; Russell-Jones D; Zinman B
    Diabetes Obes Metab; 2013 Jan; 15(1):42-54. PubMed ID: 22862847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes.
    Wijkman MO; Dena M; Dahlqvist S; Sofizadeh S; Hirsch I; Tuomilehto J; Mårtensson J; Torffvit O; Imberg H; Saeed A; Lind M
    J Clin Hypertens (Greenwich); 2019 Jan; 21(1):105-115. PubMed ID: 30515978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
    Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
    Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.
    Matikainen N; Söderlund S; Björnson E; Pietiläinen K; Hakkarainen A; Lundbom N; Taskinen MR; Borén J
    Diabetes Obes Metab; 2019 Jan; 21(1):84-94. PubMed ID: 30073766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.